NAD+ vs. Epithalon: separating signal from supplement hype

What did @whackktulaz actually say?

The creator compared NAD+ and Epithalon as complementary anti-aging tools, framing NAD+ as "fuel for your cells" that supports energy production, DNA repair, and cognitive function, and Epithalon as a peptide that "works on the pineal gland" to activate cellular repair by increasing telomerase activity. They gave specific dosing windows, 100-300mg for NAD+ injected subcutaneously two to three times weekly, and 5-10mg daily for Epithalon over 10-20 day cycles repeated a few times per year. The whole thing was packaged under the familiar "research protocol" framing, with a closing suggestion to stack both compounds or use them separately.

The video has 24,500 views as of this writing. That reach matters when the claims involve injectable compounds with limited human safety data. So let's actually look at what holds up.

Does the science back this up?

Partially, but the confidence level in the video is running well ahead of the evidence, especially for Epithalon in humans. NAD+ precursor research is more developed, but subcutaneous NAD+ injection is a different conversation than oral NMN or NR supplementation.

For NAD+, the biological story is real. NAD+ levels decline with age, and this has been linked to mitochondrial dysfunction and impaired DNA repair. Yoshino et al. (2021, Science) showed that NMN supplementation improved muscle insulin sensitivity in postmenopausal women. Cantó et al. (2012, Cell Metabolism) connected NAD+ precursor levels to SIRT1 and SIRT3 activation in animal models. That said, most of the compelling human data involves oral NMN or NR, not injected NAD+. The intravenous NAD+ space has some clinical use in addiction medicine contexts, but subcutaneous injection protocols at the doses described here lack robust published safety or efficacy data in healthy humans.

For Epithalon, the honest summary is this: it is a synthetic tetrapeptide derived from the pineal gland extract Epithalamin, and telomerase-related findings exist, but almost entirely in cell cultures and animal models. Khavinson et al. (2003, Neuroendocrinology Letters) reported increased telomerase activity in human somatic cells in vitro. Anisimov et al. (2003, Mechanisms of Ageing and Development) found increased lifespan in mice. There are no published randomized controlled trials in humans. Framing this as an established anti-aging tool is a significant overreach.

What did they get wrong (or right)?

They got the basic biology directionally right. NAD+ does play a role in DNA repair and energy metabolism. Telomerase activity is genuinely connected to cellular aging. Framing NAD+ as "fuel" and Epithalon as a maintenance signal is a simplification, but not a wildly inaccurate one for a short video.

Where it breaks down is the confidence of the delivery and the dosing specifics. Presenting "5 to 10 milligrams per day for 10 to 20 days" as a "common research protocol" implies a level of established, peer-reviewed consensus that simply does not exist for Epithalon in humans. These doses circulate in biohacking communities and peptide vendor literature, not clinical trial registries. The claim that Epithalon "works on the pineal gland" also needs context. Epithalon is derived from research on the pineal gland, but calling it a direct pineal modulator in humans is speculative.

The framing of viewers as "test subjects" conducting their own "experiments" is a rhetorical move that sidesteps the fact that most people watching this are not researchers and have no access to the monitoring needed to do this safely. That framing does real work in normalizing unmonitored self-injection of unregulated compounds.

What should you actually know?

If you are genuinely interested in NAD+ optimization, the oral precursor research is more mature and the risk profile is better characterized. Randomized controlled trials exist for NMN and NR supplementation in humans. Subcutaneous NAD+ injection is used in some clinical settings, but the protocols described here are not derived from peer-reviewed dose-finding studies.

For Epithalon, the honest answer is that we do not have human RCT data. Animal and in vitro findings are interesting and worth following, but they do not justify confident dosing recommendations to a general TikTok audience. The compound is not FDA-approved, is not available through licensed pharmacies as a regulated product, and any sourcing happens outside of standard pharmaceutical supply chains, which creates real quality and purity concerns.

Both compounds may become more interesting as research develops. Right now, the evidence base is thin enough that anyone who tells you exactly how many milligrams to inject and how many times per week should be asked to produce the RCT that justifies that specific number. Most of the time, that citation will not appear.

• NAD+ research in humans is real but mostly based on oral precursors, not subcutaneous injection
• Epithalon human evidence does not currently support the level of certainty in this video
• Dosing figures for both compounds come largely from community protocols, not clinical trials
• Unmonitored injection of either compound carries risks that the video does not address